Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO) (COMRADE-C)
2016年9月21日 更新者:Novartis Pharmaceuticals
A 6-month Multicenter, Randomized, Double-masked Phase IIIb-study Comparing the Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Visual Impairment Due to Macular Edema Following Central Retinal Vein Occlusion (CRVO)
This clinical trial is designed to compare ranibizumab in comparison with Dexamethasone implant® after 6 months of treatment.
In the study arm Lucentis will be given monthly in a pro re nata scheme whereas the comparator Dexamethasone implant is given once at Month 0 with sham injections PRN afterwards.
研究概览
研究类型
介入性
注册 (实际的)
243
阶段
- 第三阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
-
Budapest、匈牙利、1083
- Novartis Investigative Site
-
Budapest、匈牙利、1133
- Novartis Investigative Site
-
Szeged、匈牙利、H-6720
- Novartis Investigative Site
-
-
-
-
-
Augsburg、德国、85155
- Novartis Investigative Site
-
Bad Rothenfelde、德国、49215
- Novartis Investigative Site
-
Berlin、德国、10713
- Novartis Investigative Site
-
Berlin、德国、13353
- Novartis Investigative Site
-
Bonn、德国、53127
- Novartis Investigative Site
-
Bremen、德国、28209
- Novartis Investigative Site
-
Chemnitz、德国、09116
- Novartis Investigative Site
-
Darmstadt、德国、64298
- Novartis Investigative Site
-
Dortmund、德国、44137
- Novartis Investigative Site
-
Dresden、德国、01307
- Novartis Investigative Site
-
Duesseldorf、德国、40225
- Novartis Investigative Site
-
Frankfurt、德国、60318
- Novartis Investigative Site
-
Freiburg i. Br、德国、79106
- Novartis Investigative Site
-
Glauchau、德国、08371
- Novartis Investigative Site
-
Göttingen、德国、37075
- Novartis Investigative Site
-
Hagen、德国、58097
- Novartis Investigative Site
-
Hamburg、德国、20246
- Novartis Investigative Site
-
Hamburg、德国、22417
- Novartis Investigative Site
-
Homburg、德国、66421
- Novartis Investigative Site
-
Ingolstadt、德国、85049
- Novartis Investigative Site
-
Karlsruhe、德国、76133
- Novartis Investigative Site
-
Karlsruhe、德国、76199
- Novartis Investigative Site
-
Kiel、德国、24105
- Novartis Investigative Site
-
Koeln、德国、50935
- Novartis Investigative Site
-
Lauterbach、德国、36341
- Novartis Investigative Site
-
Leipzig、德国、04103
- Novartis Investigative Site
-
Ludwigshafen、德国、67063
- Novartis Investigative Site
-
Minden、德国、32427
- Novartis Investigative Site
-
Muelheim、德国、45468
- Novartis Investigative Site
-
Muenster、德国、48149
- Novartis Investigative Site
-
Muenster、德国、48145
- Novartis Investigative Site
-
München、德国、81675
- Novartis Investigative Site
-
München、德国、80336
- Novartis Investigative Site
-
Nuernberg、德国、90491
- Novartis Investigative Site
-
Recklinghausen、德国、45657
- Novartis Investigative Site
-
Regensburg、德国、93042
- Novartis Investigative Site
-
Sulzbach、德国、66280
- Novartis Investigative Site
-
Tübingen、德国、72076
- Novartis Investigative Site
-
Ulm、德国、89075
- Novartis Investigative Site
-
Wolfsburg、德国、38442
- Novartis Investigative Site
-
Würzburg、德国、97080
- Novartis Investigative Site
-
-
-
-
-
Bydgoszcz、波兰
- Novartis Investigative Site
-
Bytom、波兰、41-902
- Novartis Investigative Site
-
-
-
-
-
Birmingham、英国、B152WB
- Novartis Investigative Site
-
Birmingham、英国、B18 7QU
- Novartis Investigative Site
-
Bradford、英国、BD9 6RJ
- Novartis Investigative Site
-
Cheshire、英国、CW1 4QJ
- Novartis Investigative Site
-
Colchester、英国、CO3 3NB
- Novartis Investigative Site
-
Derby、英国、DE22 3NE
- Novartis Investigative Site
-
Gloucester、英国、GL1 3NN
- Novartis Investigative Site
-
Guildford, Surrey、英国、GU2 5XX
- Novartis Investigative Site
-
Kent、英国、CT1 3NG
- Novartis Investigative Site
-
Leeds、英国、LS9 7TF
- Novartis Investigative Site
-
London、英国、SE1 7EH
- Novartis Investigative Site
-
Manchester、英国、M13 9WH
- Novartis Investigative Site
-
Middlesborough、英国、TS4 3BW
- Novartis Investigative Site
-
Nottingham、英国、NG7 2UH
- Novartis Investigative Site
-
Portsmouth、英国、PO6 3LY
- Novartis Investigative Site
-
Rugby、英国、CV22 5PX
- Novartis Investigative Site
-
Westcliff-on-Sea、英国、SS0 0RY
- Novartis Investigative Site
-
York、英国、YO31 8HE
- Novartis Investigative Site
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Patients diagnosed with visual impairment due to macular edema following CRVO
- Diagnosis of CRVO at maximum 6 months prior to Screening
- BCVA using ETDRS charts of 20/40 to 20/400 in the study eye
Exclusion Criteria:
- Media clarity, pupillary dilation and patient cooperation not sufficient for adequate fundus photographs
- Central retinal thickness (CRT) < 250 µm in the study eye
- Prior episode of RVO in the study eye
- Active formation of new vessels in the study eye
- Anti-VEGF-treatment in the study or the fellow eye 3 months prior to Baseline
- IOP ≥ 30mmHg or uncontrolled glaucoma; patients may be re-screened after 1 month if they have undergone glaucoma treatment
- Improvement of > 10 letters on BCVA between Screening and Baseline
Other protocol-defined inclusion/exclusion criteria may apply
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:护理标准
|
|
|
实验性的:雷珠单抗
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Mean Average BCVA Change From Month 1 Through Month 6 to Baseline
大体时间:Baseline, month 6
|
the average of the changes in BCVA (letters) from baseline to any post-baseline visit, i.e. the mean of six differences to baseline for the six post-baseline visits at month 1 to 6. BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters.
An ETDRS visual acuity score of 85 is pproximately 20/20.
An increased score indicates improvement in acuity
|
Baseline, month 6
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
达到显着改善的时间 ≥ 15 个字母
大体时间:基线,第 6 个月
|
时间通过 Kaplan-Maier-Method 分析,调整了 dropouts 的计算
|
基线,第 6 个月
|
|
中央视网膜厚度 (CRT) 随时间的变化
大体时间:基线,第 6 个月
|
使用光学相干断层扫描 (OCT) 测量视网膜厚度。
图像由中央阅读中心审查,以确保标准化评估
|
基线,第 6 个月
|
|
根据简表 (36) 健康调查 (SF-36) 问卷调查的生活质量变化
大体时间:基线,第 6 个月
|
SF-36 摘要测量是基于常模的分数,平均值 = 50,SD = 10。
分数越高表明健康状况越好
|
基线,第 6 个月
|
|
根据欧洲生活质量 (EQ-5D) 问卷调查的生活质量变化
大体时间:基线,第 6 个月
|
EQ-5D 视觉模拟量表的范围从 0 到 100,0 代表最差的健康状态,100 代表最好的健康状态。
|
基线,第 6 个月
|
|
Mean BCVA Change at Month 6
大体时间:Baseline, month 6
|
The analysis was performed by an analysis of covariance (ANCOVA) model with average change in BCVA (letters) from Visit 1 through Visit 6 as dependent variable, and with the factors center, treatment and covariate baseline BCVA as predictors
|
Baseline, month 6
|
|
Number of Patients Gaining / Losing ≥ 15 / 10 / 5 Letters
大体时间:Baseline, 6 month
|
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters.
An ETDRS visual acuity score of 85 is approximately 20/20.
An increased score indicates improvement in acuity.
This outcome assessed the number of participants who gained 15, 10 or 5 more letters of visual acuity at month 6 as compared with baseline
|
Baseline, 6 month
|
|
Change Over Time in BCVA
大体时间:Baseline, month 6
|
The analysis was performed by an analysis of covariance (ANCOVA) model with average change in BCVA (letters) from Visit 1 through Visit 6 as dependent variable, and with the factors center, treatment and covariate baseline BCVA as predictors
|
Baseline, month 6
|
|
Changes in the Quality of Life According to the National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) Questionnaires
大体时间:Baseline, month 6
|
The VFQ-25 composite and subscale scores range from 0 to 100, a higher score indicating better functioning.
The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision.
The scores on the subscales were added together for a total score, which ranged from 0 to 100.
A higher score indicated improvement in quality of life due to vision function
|
Baseline, month 6
|
|
Increase Rate of the Internal Ocular Pressure (IOP ) : Patients With ≥10% Increase in IOP Compared to Baseline
大体时间:Baseline, month 6
|
The proportion of patients with ≥ 10% increase in Internal Ocular Pressure (IOP) compared to baseline at any post-baseline visit.
|
Baseline, month 6
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2011年8月1日
初级完成 (实际的)
2014年1月1日
研究完成 (实际的)
2014年1月1日
研究注册日期
首次提交
2011年7月14日
首先提交符合 QC 标准的
2011年7月15日
首次发布 (估计)
2011年7月18日
研究记录更新
最后更新发布 (估计)
2016年9月27日
上次提交的符合 QC 标准的更新
2016年9月21日
最后验证
2016年9月1日
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- CRFB002EDE18
- 2011-001020-38 (EudraCT编号)
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.